CAS: 119020-01-8; (S)-1-Boc-2-(Aminomethyl)Pyrrolidine

相似化合物

1190890-11-9 177911-87-4 259537-92-3

上下游产品

CAS号168049-26-1 (S)-2-(叠氮甲基)-1-... | CAS号281197-55-5 tert-butyl (2S)... | CAS号69610-40-8 B°C-L-脯氨醇 | CAS号86661-32-7 (S)-2-(甲苯磺酰氧基甲基... | CAS号24424-99-5 二碳酸二叔丁酯 | CAS号23356-96-9 L-脯氨醇 | CAS号228244-04-0 |S|-(-)-1-B°C-2... | CAS号15761-39-4 B°C-L-脯氨酸 | CAS号147-85-3 脯氨酸 | CAS号929048-08-8 (S)-2-[[(苄氧羰基)氨...

Tert-Butyl (2S)-2-{[(Methylsulfonyl)Oxy]Methyl}-Pyrrolidine-1-Carboxylate置于palladium On Activated Charcoal Sodium Azide,氢气体系中,用 四氢呋喃,N,N-二甲基甲酰胺 用作溶剂,化学反应 20.0H,反应生成S-叔丁氧羰基-2-(氨基乙基)吡咯烷
参考文献:4-取代的脯氨酰磺酰胺作为羟醛反应的对映选择性有机催化剂
标题:4-取代的脯氨酰磺酰胺作为羟醛反应的对映选择性有机催化剂
摘要:制备了一系列脯氨酰和4-取代的脯氨酰磺酰胺,并对其作为不对称羟醛反应的有机催化剂进行了评价.使用脯氨酰甲磺酰胺,4-苄氧基-脯氨酰甲磺酰胺和甲苯磺酰胺和 4-羟基脯氨酰甲苯磺酰胺,与使用脯氨酸本身观测到的相比,得到的羟醛产物对映体过量 (Ee) 要高得多.此外,这些新催化剂的使用量可能低于脯氨酸,因为它们在有机溶剂中的溶解度有所提高.
Doi:10.1055/s-2005-870026

专利信息

专利号:US-2025129021-A1
优先权日:2023-09-19
标 题:Small molecule protein synthesis modulators
发明人：GYGI DAVID; BAHMANYAR SOGOLE SAMI; HAMANN LAWRENCE
权利人:INTERDICT BIO INC
摘要:The present disclosure provides compounds of the formulae herein (e.g., Formula (I), Formula (V)), and pharmaceutically acceptable salts thereof, which are useful for modulating protein synthesis (e.g., modulating synthesis of BCL-2, MYC, CCND1, MCL-1, ALK, KRAS-G12D). The present disclosure also provides pharmaceutical compositions and kits comprising the compounds, or pharmaceutically acceptable salts thereof, and methods of treating or preventing diseases or disorders (e.g., diseases or disorders associated with BCL-2, MYC, CCND1, MCL-1, ALK, KRAS-G12D) by administering to a subject in need thereof the compounds, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof.

专利号:US-8895747-B2
优先权日:2009-07-27
标 题 :Method and substances for preparation of N-substituted pyridinium compounds
发明人：HEINDL DIETER; MAERZ HERIBERT; SCHMIDT AXEL
权利人:HEINDL DIETER; MAERZ HERIBERT; SCHMIDT AXEL; ROCHE DIAGNOSTICS OPERATIONS
摘要:Methods for the synthesis of N-substituted pyridinium compounds by using an N-heteroaryl substituted pyridinium salt (Zincke salt) and reacting it with a nucleophilic amine are provided. Novel purine-substituted pyridyl compounds, which may be useful reagents in the above reaction, are also disclosed.

专利号:US-8772301-B2
优先权日:2009-12-18
标题 :Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
发明人：HARDY LARRY WENDELL; HEFFERNAN MICHELE L R; WU FRANK XINHE; SPEAR KERRY L; SARASWAT LAKSHMI D
权利人:HARDY LARRY WENDELL; HEFFERNAN MICHELE L R; WU FRANK XINHE; SPEAR KERRY L; SARASWAT LAKSHMI D; SUNOVION PHARMACEUTICALS INC
摘要:Provided herein are compounds and methods of synthesis thereof. The compounds set forth herein are useful for the treatment, prevention, and/or management of various disorders, such as neurological disorders, neurodegenerative disorders, neuropsychiatric disorders, disorders of cognition, learning or memory, gastrointestinal disorders, lower urinary tract disorder, and cancer. Compounds set forth herein modulate the activity of metabotropic glutamate receptor 5 (mGluR5) in the central nervous system or the periphery. Pharmaceutical formulations containing the compounds and their methods of use are also provided herein.

专利号:EP-1836163-B1
优先权日:2004-12-23
标题 :Pyrrolidine derivatives for the treatment of a disease depending on the activity of renin
发明人：BREITENSTEIN WERNER; COTTENS SYLVAIN; EHRHARDT CLAUS; JACOBY EDGAR; LORTHIOIS EDWIGE LILIANE JEANNE; MAIBAUM JUERGEN KLAUS; OSTERMANN NILS; SELLNER HOLGER; SIMIC OLIVER
权利人:NOVARTIS AG
摘要:Novel 3-mono-, 3,4-di- and 3,4,4,-tri-substituted pyrrolidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on inappropriate activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on inappropriate activity of renin; the use of a compound of that class in the treatment of a disease that depends on inappropriate activity of renin; pharmaceutical formulations comprising a said substituted pyrrolidine compound, and/or a method of treatment comprising administering a said substituted pyrrolidine compound, a method for the manufacture of said substituted pyrrolidine compounds, and novel intermediates and partial steps for their synthesis are described. The substituted pyrrolidine compounds are especially of the formula I wherein the substituents are as described in the specification.